Vaxcyte Stock Analysis

Vaxcyte Stock Analysis Notes

About 100.0% of the company shares are owned by institutional investors. The book value of Vaxcyte was at this time reported as 27.47. The company recorded a loss per share of 4.6. Vaxcyte had not issued any dividends in recent years. Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. Vaxcyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people. To find out more about Vaxcyte contact Grant MBA at 650 837 0111 or learn more at https://vaxcyte.com.

Vaxcyte Investment Alerts

Vaxcyte Upcoming and Recent Events

Vaxcyte Largest EPS Surprises

View All Earnings Estimates

Vaxcyte Environmental, Social, and Governance (ESG) Scores

Vaxcyte Stock Institutional Investors

Note, although Vaxcyte's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Vaxcyte Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 10.71 B.

Vaxcyte Profitablity

Management Efficiency

Vaxcyte has return on total asset (ROA) of (0.1494) % which means that it has lost $0.1494 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2106) %, meaning that it created substantial loss on money invested by shareholders. Vaxcyte's management efficiency ratios could be used to measure how well Vaxcyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.3 in 2024. Return On Capital Employed is likely to drop to -0.39 in 2024. At this time, Vaxcyte's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 1.2 B in 2024, whereas Other Assets are likely to drop 0.95 in 2024.

Technical Drivers

As of the 22nd of November, Vaxcyte has the Risk Adjusted Performance of 0.0435, coefficient of variation of 2153.13, and Semi Deviation of 2.23. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vaxcyte, as well as the relationship between them.

Vaxcyte Price Movement Analysis

Vaxcyte Insider Trading Activities

Vaxcyte Outstanding Bonds

Vaxcyte Predictive Daily Indicators

Vaxcyte Corporate Filings

Vaxcyte Forecast Models

Vaxcyte's time-series forecasting models are one of many Vaxcyte's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vaxcyte's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Vaxcyte prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Vaxcyte shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Vaxcyte. By using and applying Vaxcyte Stock analysis, traders can create a robust methodology for identifying Vaxcyte entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vaxcyte analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Vaxcyte analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Vaxcyte stock analysis indicators help investors evaluate how Vaxcyte stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Vaxcyte shares will generate the highest return on investment. By understating and applying Vaxcyte stock analysis, traders can identify Vaxcyte position entry and exit signals to maximize returns.

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.